Simmons, D.Rudland, V.L.Wong, V.Flack, J.Mackie, A.Ross, G.P.Coat, S.Dalal, R.Hague, B.M.Cheung, N.W.2025-07-142025-07-142020Australian and New Zealand Journal of Obstetrics and Gynaecology, 2020; 60(5):660-6660004-86661479-828Xhttps://hdl.handle.net/2440/145923The balance between avoiding severe acute respiratory syndrome coronavirus-2 contagion and reducing wider clinical risk is unclear for gestational diabetes mellitus (GDM) testing. Recent recommendations promote diagnostic approaches that limit collection but increase undiagnosed GDM, which potentially increases adverse pregnancy outcome risks. The most sensitive approach to detecting GDM at 24–28 weeks beyond the two-hour oral glucose tolerance test (OGTT) is a onehour OGTT (88% sensitivity). Less sensitive approaches use fasting glucose alone (≥5.1 mmol/L: misses 44–54% GDM) or asking ~20% of women for a second visit (fasting glucose 4.7–5.0 mmol/L (62–72% sensitive)). Choices should emphasise local and patient decision-making.en© 2020 The Royal Australian and New Zealand College of Obstetricians and Gynaecologistsdiagnosis; gestational diabetes mellitus; macrosomia; screening; stillbirthHumansPregnancy Complications, InfectiousPneumonia, ViralCoronavirus InfectionsDiabetes, GestationalBlood GlucoseGlucose Tolerance TestPrenatal DiagnosisPregnancy OutcomePatient IsolationRisk AssessmentInfection ControlGestational AgePregnancyAdultFemalePandemicsClinical Decision-MakingCOVID-19Options for screening for gestational diabetes mellitus during the SARS-CoV-2 pandemicJournal article10.1111/ajo.132242024-05-02541560Coat, S. [0000-0002-3836-2854]Hague, B.M. [0000-0002-5355-2955]